Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
the Board of Directors has elected Bruce L.A. Carter, Ph.D. as
non-executive Chairman of the Board. Dr. Carter has been an independent
director of Enanta since November 2013. He currently serves as the Chair
of the Compensation Committee and is a member of the Nominating and
Corporate Governance Committee.
“Since his appointment in 2013, Bruce has used his extensive industry
experience to provide great judgment and strong leadership to the Enanta
Board. We look forward to his continuing leadership in his new role at
Enanta,” stated Jay R. Luly, Ph.D., President and Chief Executive
Officer.
Dr. Carter has extensive experience in the pharmaceutical and
biotechnology industries, having served as Corporate Executive Vice
President and Chief Scientific Officer of Novo Nordisk and as an
executive in research at ZymoGenetics and G.D.Searle. Dr. Carter was the
President and CEO of ZymoGenetics until 2009, and served most recently
as the Executive Chairman of Immune Design Corp. until 2011. He has
served as a director of several biotechnology companies, including as
non-executive Chairman of the Board of ZymoGenetics when it was sold to
Bristol-Myers Squibb in 2010, and currently serves as a director of Dr.
Reddy’s Laboratories and Xencor, Inc. Dr. Carter is also an Affiliate
Professor, Department of Biochemistry at the University of Washington,
Seattle, Washington and serves as Board Chair of the Infectious Disease
Research Institute in Seattle, Washington and is on the Board of
Directors of the TB Alliance.
Dr. Carter received a B.Sc. with Honors in Botany from the University of
Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth
College, University of London.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta has
developed novel protease and NS5A inhibitors that are members of the
direct-acting-antiviral (DAA) inhibitor classes designed for use against
the hepatitis C virus (HCV). Enanta’s protease inhibitors partnered with
AbbVie include paritaprevir, which is contained in AbbVie’s marketed DAA
regimens for HCV, and ABT-493, Enanta’s next-generation protease
inhibitor which AbbVie is developing in phase 3 studies in combination
with ABT-530, AbbVie’s next-generation NS5A inhibitor. Enanta also has
discovered EDP-494, a host-targeted antiviral (HTA) inhibitor for HCV
targeted against cyclophilin, which Enanta plans to study in a phase 1
clinical trial in the first quarter of 2016. In addition, Enanta has a
preclinical program in non-alcoholic steatohepatitis, or NASH, which is
a condition that results in liver inflammation and liver damage caused
by a buildup of fat in the liver.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151214005108/en/
Copyright Business Wire 2015